Skip to main content
NASDAQ:KRBP

Kiromic BioPharma Competitors

$5.79
+0.49 (+9.25 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.95
$5.92
50-Day Range
$5.30
$9.88
52-Week Range
$4.95
$18.50
Volume16,337 shs
Average Volume19,451 shs
Market Capitalization$42.46 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Kiromic BioPharma (NASDAQ:KRBP) Vs. AGTC, FENC, GMDA, LOGC, ERYP, and INMB

Should you be buying KRBP stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Kiromic BioPharma, including Applied Genetic Technologies (AGTC), Fennec Pharmaceuticals (FENC), Gamida Cell (GMDA), LogicBio Therapeutics (LOGC), ERYTECH Pharma (ERYP), and INmune Bio (INMB).

Kiromic BioPharma (NASDAQ:KRBP) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Kiromic BioPharma and Applied Genetic Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kiromic BioPharmaN/AN/AN/A
Applied Genetic TechnologiesN/A-73.06%-53.25%

Institutional & Insider Ownership

57.9% of Applied Genetic Technologies shares are owned by institutional investors. 7.5% of Applied Genetic Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Kiromic BioPharma and Applied Genetic Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiromic BioPharmaN/AN/AN/AN/AN/A
Applied Genetic Technologies$2.45 million67.71$-45,890,000.00($2.17)-1.79

Kiromic BioPharma has higher earnings, but lower revenue than Applied Genetic Technologies.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kiromic BioPharma and Applied Genetic Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kiromic BioPharma0000N/A
Applied Genetic Technologies00603.00

Applied Genetic Technologies has a consensus price target of $17.5833, suggesting a potential upside of 353.18%. Given Applied Genetic Technologies' higher possible upside, analysts plainly believe Applied Genetic Technologies is more favorable than Kiromic BioPharma.

Summary

Applied Genetic Technologies beats Kiromic BioPharma on 5 of the 7 factors compared between the two stocks.

Kiromic BioPharma (NASDAQ:KRBP) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Kiromic BioPharma and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kiromic BioPharmaN/AN/AN/A
Fennec PharmaceuticalsN/A-84.34%-75.51%

Institutional & Insider Ownership

53.6% of Fennec Pharmaceuticals shares are owned by institutional investors. 9.1% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Kiromic BioPharma and Fennec Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiromic BioPharmaN/AN/AN/AN/AN/A
Fennec PharmaceuticalsN/AN/A$-12,770,000.00($0.64)-9.86

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kiromic BioPharma and Fennec Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kiromic BioPharma0000N/A
Fennec Pharmaceuticals00403.00

Fennec Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 129.79%. Given Fennec Pharmaceuticals' higher possible upside, analysts plainly believe Fennec Pharmaceuticals is more favorable than Kiromic BioPharma.

Summary

Fennec Pharmaceuticals beats Kiromic BioPharma on 4 of the 6 factors compared between the two stocks.

Kiromic BioPharma (NASDAQ:KRBP) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Kiromic BioPharma and Gamida Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kiromic BioPharmaN/AN/AN/A
Gamida CellN/A-112.47%-65.09%

Earnings & Valuation

This table compares Kiromic BioPharma and Gamida Cell's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiromic BioPharmaN/AN/AN/AN/AN/A
Gamida CellN/AN/A$-34,350,000.00($1.69)-3.84

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kiromic BioPharma and Gamida Cell, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kiromic BioPharma0000N/A
Gamida Cell00503.00

Gamida Cell has a consensus price target of $20.25, suggesting a potential upside of 212.02%. Given Gamida Cell's higher possible upside, analysts plainly believe Gamida Cell is more favorable than Kiromic BioPharma.

Kiromic BioPharma (NASDAQ:KRBP) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Kiromic BioPharma and LogicBio Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiromic BioPharmaN/AN/AN/AN/AN/A
LogicBio TherapeuticsN/AN/A$-40,130,000.00($1.78)-2.66

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kiromic BioPharma and LogicBio Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kiromic BioPharma0000N/A
LogicBio Therapeutics00303.00

LogicBio Therapeutics has a consensus price target of $18.50, suggesting a potential upside of 290.30%. Given LogicBio Therapeutics' higher possible upside, analysts plainly believe LogicBio Therapeutics is more favorable than Kiromic BioPharma.

Profitability

This table compares Kiromic BioPharma and LogicBio Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kiromic BioPharmaN/AN/AN/A
LogicBio TherapeuticsN/A-117.64%-76.85%

Institutional & Insider Ownership

33.8% of LogicBio Therapeutics shares are owned by institutional investors. 23.4% of LogicBio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

LogicBio Therapeutics beats Kiromic BioPharma on 4 of the 6 factors compared between the two stocks.

ERYTECH Pharma (NASDAQ:ERYP) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares ERYTECH Pharma and Kiromic BioPharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ERYTECH PharmaN/AN/A$-70,180,000.00($3.92)-1.75
Kiromic BioPharmaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ERYTECH Pharma and Kiromic BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ERYTECH Pharma0000N/A
Kiromic BioPharma0000N/A

Profitability

This table compares ERYTECH Pharma and Kiromic BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ERYTECH PharmaN/AN/AN/A
Kiromic BioPharmaN/AN/AN/A

Institutional and Insider Ownership

6.5% of ERYTECH Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ERYTECH Pharma beats Kiromic BioPharma on 1 of the 1 factors compared between the two stocks.

INmune Bio (NASDAQ:INMB) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares INmune Bio and Kiromic BioPharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INmune BioN/AN/A$-7,680,000.00($0.75)-13.04
Kiromic BioPharmaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for INmune Bio and Kiromic BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
INmune Bio00503.00
Kiromic BioPharma0000N/A

INmune Bio currently has a consensus target price of $21.20, suggesting a potential upside of 116.77%. Given INmune Bio's higher possible upside, equities research analysts clearly believe INmune Bio is more favorable than Kiromic BioPharma.

Profitability

This table compares INmune Bio and Kiromic BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
INmune BioN/A-41.18%-39.34%
Kiromic BioPharmaN/AN/AN/A

Institutional and Insider Ownership

7.4% of INmune Bio shares are owned by institutional investors. 58.9% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

INmune Bio beats Kiromic BioPharma on 4 of the 6 factors compared between the two stocks.


Kiromic BioPharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.88+5.4%$165.88 million$2.45 million-1.82Upcoming Earnings
News Coverage
Gap Down
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.31+1.7%$164.08 millionN/A-7.70Earnings Announcement
Analyst Revision
News Coverage
Gamida Cell logo
GMDA
Gamida Cell
1.4$6.49+2.9%$157.19 millionN/A-4.54Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$4.74+6.5%$152.44 millionN/A-2.96Earnings Announcement
Analyst Revision
News Coverage
Gap Down
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.87+5.2%$148.59 millionN/A-1.75Gap Down
INmune Bio logo
INMB
INmune Bio
1.5$9.78+5.0%$146.05 millionN/A-10.08Analyst Downgrade
Gap Down
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.74+8.5%$145.76 millionN/A0.00Earnings Announcement
News Coverage
Gap Down
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$7.63+2.4%$132.64 millionN/A-2.38Gap Down
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.3$10.00+2.0%$132.41 million$2.33 million0.00Earnings Announcement
News Coverage
Champions Oncology logo
CSBR
Champions Oncology
1.8$9.55+5.0%$127.88 million$32.12 million-73.46Gap Down
Axcella Health logo
AXLA
Axcella Health
1.6$3.36+0.9%$126.75 millionN/A-1.56Analyst Revision
News Coverage
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.38+4.7%$122.76 millionN/A-3.22Gap Down
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.19+5.9%$119.21 millionN/A-1.51Analyst Revision
Gap Down
PolarityTE logo
PTE
PolarityTE
1.5$0.98+26.6%$118.15 million$5.65 million-0.58Earnings Announcement
Unusual Options Activity
News Coverage
Gap Up
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.7$11.50+5.3%$117.60 millionN/A0.00Insider Buying
Gap Down
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$3.65+3.0%$115.85 million$20,000.000.00Upcoming Earnings
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.76+6.9%$103.21 million$23.05 million-1.67Analyst Downgrade
Analyst Revision
Gap Down
Dyadic International logo
DYAI
Dyadic International
1.3$3.73+2.9%$102.78 million$1.68 million-10.97
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$9.01+3.7%$101.17 millionN/A0.00Analyst Upgrade
Gap Down
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.01+0.5%$97.06 million$20.92 million-1.16Earnings Announcement
News Coverage
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.01+4.0%$96.12 million$140,000.000.00Upcoming Earnings
Gap Down
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$6.16+5.7%$95.49 million$3 million-1.98Gap Down
ENTX
Entera Bio
1.2$2.93+0.3%$69.44 million$240,000.00-4.31Upcoming Earnings
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$3.76+22.3%$65.03 million$10,000.000.00Upcoming Earnings
Gap Up
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.10+3.6%$63.37 millionN/A-0.87Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.68+1.6%$58.92 million$420,000.00-1.38Earnings Announcement
News Coverage
Gap Down
BioCardia logo
BCDA
BioCardia
1.2$3.43+3.2%$57.60 million$710,000.00-1.77Earnings Announcement
News Coverage
Gap Down
Brickell Biotech logo
BBI
Brickell Biotech
1.6$0.82+3.6%$55.08 million$7.92 million-0.34Earnings Announcement
Analyst Upgrade
News Coverage
Gap Up
Genetic Technologies logo
GENE
Genetic Technologies
0.4$3.61+0.3%$54.25 million$10,000.000.00
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.02+1.0%$51.03 million$1.45 million-0.36News Coverage
Organovo logo
ONVO
Organovo
0.7$6.84+2.8%$48.68 million$2.20 million0.00Upcoming Earnings
News Coverage
Microbot Medical logo
MBOT
Microbot Medical
1.3$6.72+3.0%$47.77 millionN/A0.00Upcoming Earnings
Windtree Therapeutics logo
WINT
Windtree Therapeutics
2.3$1.76+4.5%$46.21 million$200,000.00-0.73Earnings Announcement
High Trading Volume
News Coverage
Acorda Therapeutics logo
ACOR
Acorda Therapeutics
1.4$4.49+4.9%$42.61 million$192.41 million0.81Gap Down
BiondVax Pharmaceuticals logo
BVXV
BiondVax Pharmaceuticals
0.5$2.83+8.1%$32.13 millionN/A-0.94News Coverage
Gap Down
Titan Pharmaceuticals logo
TTNP
Titan Pharmaceuticals
1.2$2.32+3.4%$22.88 million$3.61 million-0.31Upcoming Earnings
Gap Down
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.